RxSight (RXST) EBIT (2020 - 2026)

RxSight (RXST) has reported EBIT for 7 consecutive years, with -$13.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT rose 1.45% year-over-year to -$13.8 million; the trailing twelve-month figure through Jun 2026 stood at -$55.1 million (down 160.05% YoY), and the FY2025 full-year result was -$48.2 million, down 30.62% from the prior year.
• EBIT climbed to -$13.8 million in Q2 2026 per RXST's latest filing, from -$17.8 million in the prior quarter.
• Across five years, EBIT topped out at $16.6 million in Q1 2022 and bottomed at -$17.8 million in Q1 2026.
• Historically, EBIT has averaged -$3.6 million across 5 years, with a median of -$10.0 million in 2023.
• The sharpest annual moves came in 2022 and 2026: EBIT soared 249.08% in 2022, then sank 266.63% in 2026.
• Over 5 years, EBIT stood at -$15.0 million in 2022, then gained by 27.51% to -$10.9 million in 2023, then climbed by 20.22% to -$8.7 million in 2024, then sank by 30.33% to -$11.3 million in 2025, then dropped by 22.12% to -$13.8 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$13.8 million, -$17.8 million, and -$11.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.